TransMedics Group (NASDAQ:TMDX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

TransMedics Group (NASDAQ:TMDX) had its price objective raised by stock analysts at JPMorgan Chase & Co. from $73.00 to $85.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential downside of 3.67% from the company’s previous close.

TMDX has been the topic of a number of other reports. Barclays began coverage on shares of TransMedics Group in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. UBS Group decreased their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating for the company in a report on Wednesday, August 5th. Canaccord Genuity Group upped their target price on shares of TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research note on Friday. Zacks Research upgraded shares of TransMedics Group from a “strong sell” rating to a “hold” rating in a report on Monday, November 2nd. Finally, TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Tuesday, September 8th. Five analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of “Hold” and a consensus target price of $112.20.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $88.24 on Friday. The stock has a 50-day simple moving average of $79.61 and a 200 day simple moving average of $93.17. The company has a market capitalization of $3.05 billion, a PE ratio of 23.91, a P/E/G ratio of 1.18 and a beta of 2.14. The company has a current ratio of 4.53, a quick ratio of 4.15 and a debt-to-equity ratio of 1.46. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. The firm had revenue of $203.01 million for the quarter, compared to analyst estimates of $178.06 million. During the same quarter in the prior year, the firm posted $0.66 earnings per share. The company’s quarterly revenue was up 41.1% on a year-over-year basis. Research analysts forecast that TransMedics Group will post 1.50 EPS for the current year.

Insider Activity

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the acquisition, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors have recently modified their holdings of the business. Allworth Financial LP increased its holdings in TransMedics Group by 14.9% during the 3rd quarter. Allworth Financial LP now owns 2,895 shares of the company’s stock worth $242,000 after purchasing an additional 375 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of TransMedics Group by 19.6% in the third quarter. Russell Investments Group Ltd. now owns 19,612 shares of the company’s stock valued at $1,637,000 after purchasing an additional 3,211 shares in the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of TransMedics Group by 53.8% in the third quarter. Maryland State Retirement & Pension System now owns 7,775 shares of the company’s stock valued at $649,000 after purchasing an additional 2,719 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in shares of TransMedics Group by 7.4% during the third quarter. Illinois Municipal Retirement Fund now owns 17,453 shares of the company’s stock worth $1,456,000 after buying an additional 1,207 shares during the period. Finally, Fulcrum Asset Management LLP boosted its position in shares of TransMedics Group by 3,648.0% during the third quarter. Fulcrum Asset Management LLP now owns 5,622 shares of the company’s stock worth $473,000 after buying an additional 5,472 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services.

The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.